NU6027 

NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner^[1][2].

NU6027 (1 nM-100 µM; 48 h) inhibits the growth of human tumor cells with a GI₅₀ of 10±6 µM^[1].
NU6027 (0.1-25 µM; 24 h) inhibits ATR activity with an IC₅₀ of 2.8 µM in GM847KD cells. NU6027 (1-10 µM; 24 h) inhibits ATR activity with an IC₅₀ of 6.7±2.3 µM in MCF7 cells^[2].
NU6027 (4 or 10 µM; 24 h) attenuates G2/M arrest following DNA damage in MCF7 cells^[2].
NU6027 (10 µM; 24 h) significantly reduces RAD51 foci in both control and PF-01367338-treated V-C8 B2 cells^[2].
NU6027 (4 µM; 24 h) causes 82% suppression of the increase in RAD51 foci-positive cells treated by PF-01367338^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

251.28

Solid

C₁₁H₁₇N₅O₂

220036-08-8

NC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Arris CE, et, al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem. 2000 Jul 27; 43(15): 2797-804.  [Content Brief]

  [2]. Peasland A, et, al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer. 2011 Jul 26;105(3):372-81.  [Content Brief]